Guy Goodwin
FMedSci
Emeritus Professor of Psychiatry
The development of better ways to treat mood disorders
My research interests are in the treatment of bipolar disorder and the application of neuroscience and technology in understanding the neurobiology of mood disorders, with a focus on developing new treatments.
I was formerly W.A.Handley Chair of Psychiatry and head of the University department of Psychiatry (1996-2011).
I am a Fellow of the American College of Neuropsychopharmacology, and have previously held the positions of President of the British Association for Psychopharmacology (2004–2005) and of the European College of Neuropsychopharmacology (ECNP, 2013-2016).
I am an Emeritus Senior Investigator on the faculty of UK National Institute for Health Research (NIHR).
I am a Thomson Reuters highly cited researcher (top 1% in field).
Recent publications
-
Psilocybin for Treatment-Resistant Depression. Reply.
Journal article
Goodwin GM. et al, (2023), N Engl J Med, 388
-
Unblinding and demand characteristics in the treatment of depression.
Journal article
Goodwin GM. et al, (2023), J Affect Disord, 328, 1 - 5
-
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.
Journal article
Goodwin GM. et al, (2023), J Affect Disord
-
Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder.
Journal article
Joas E. et al, (2022), Pharmacogenomics J
-
Excess resource use and costs of physical comorbidities in individuals with mental health disorders: A systematic literature review and meta-analysis.
Journal article
Simon J. et al, (2022), Eur Neuropsychopharmacol, 66, 14 - 27